银杏蜜环口服溶液联合阿托伐他汀治疗冠心病心绞痛的疗效观察

目的探讨银杏蜜环口服溶液联合阿托伐他汀钙片治疗冠心病心绞痛的临床疗效。方法选取2016年5月—2018年5月青海省心脑血管病专科医院收治的176例冠心病心绞痛患者作为研究对象,将患者随机分为对照组和治疗组,每组各88例。对照组口服阿托伐他汀钙片,20 mg/次,1次/d;治疗组在对照组治疗的基础上口服银杏蜜环口服溶液,10 mL/次,3次/d。两组患者均连续治疗4周。观察两组的临床疗效和心电图疗效,比较两组的临床症状、心功能指标、血液流变学、心血管事件发生率。结果治疗后,对照组和治疗组的临床疗效总有效率分别为81.8%、94.3%,两组比较差异有统计学意义(P0.05)。治疗后,对照组和治疗组的心电图疗效总有效率分别为80.7%、93.2%,两组比较差异有统计学意义(P0.05)。治疗后,两组心绞痛发作次数、持续时间、硝酸甘油用量均明显下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组心绞痛发作次数、持续时间、硝酸甘油用量明显低于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组左室射血分数(LVEF)明显升高,左室舒张末期内径(LVEDD)、舒张早期流速峰值/舒张晚期流速峰值(E/A值)均明显下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组LVEF、LVEDD、E/A值明显优于对照组,两组比较差异有统计学意义(P0.05)。治疗后,两组血浆黏度(PV)、血细胞比容(HCT)、纤维蛋白原(FIB)和血小板聚集率(MPA)水平均明显下降,同组治疗前后比较差异有统计学意义(P0.05);且治疗组PV、HCT、FIB、MPA水平明显低于对照组,两组比较差异有统计学意义(P0.05)。随访6个月,对照组和治疗组的心血管事件发生率分别为18.2%、6.8%,两组比较差异有统计学意义(P0.05)。结论银杏蜜环口服溶液联合阿托伐他汀钙片治疗冠心病心绞痛具有较好的临床疗效,可改善患者临床症状和血液流变学,降低心血管事件发生率,具有一定的临床推广应用价值。

Clinical observation of Yinxing Mihuan Oral Liquid combined with atorvastatin in treatment of angina pectoris of coronary heart disease

Objective To investigate the effect of Yinxing Mihuan Oral Liquid combined with Atorvastatin Calcium Tablets in treatment of angina pectoris of coronary heart disease. Methods Patients (176 cases) with angina pectoris of coronary heart disease in Qinghai Province Cardiovascular and Cerebrovascular Disease Specialist Hospital from May 2016 to May 2018 were randomly divided into control and treatment groups, and each group had 88 cases. Patients in the control group were po administered with Atorvastatin Calcium Tablets, 20 mg/time, once daily. Patients in the treatment group were po administered with Yinxing Mihuan Oral Liquid on the basis of the control group, 10 mL/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies and electrocardiogram efficacies were evaluated, and clinical symptoms, cardiac function indexes, hemorheology, and the incidence of cardiovascular events in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.8% and 94.3%, respectively, and there was difference between two groups (P<0.05). After treatment, the electrocardiogram efficacies in the control and treatment groups were 80.7% and 93.2%, respectively, and there was difference between two groups (P<0.05). After treatment, the frequency and duration of angina, and the nitroglycerin dosage in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the clinical symptoms indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the LVEF in two groups were significantly increased, but LVEDD and E/A in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the cardiac function indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of PV, HCT, FIB, and MPA in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the hemorheology indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Follow up for 6 months, the incidence of cardiovascular events in the control and treatment groups were 18.2% and 6.8%, respectively, and there was difference between two groups (P<0.05). Conclusion Yinxing Mihuan Oral Liquid combined with Atorvastatin Calcium Tablets has clinical curative effect in treatment of angina pectoris of coronary heart disease, can improve the clinical symptoms and hemorheology of patients, and reduce the incidence of cardiovascular events, which has a certain clinical application value.